Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMU-130 in Metastatic Colorectal Cancer
NCT01915472Phase 2Withdrawn
- Sponsor
- Gilead Sciences
- Start
- Sep 2013
- Primary completion
- Aug 2015
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of labetuzumab govitecan in metastatic colorectal cancer (mCRC), sponsored by Gilead Sciences. Planned start Sep 2013; status: withdrawn.
02
Drugs
labetuzumab govitecan
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01915472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01915472.